Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Mouth spray could tame agonizing swallowing pain during cancer radiation

NCT ID NCT06017895

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This clinical trial tests whether a doxepin solution spray can relieve severe breakthrough pain when swallowing, a common side effect of radiation therapy for nasopharyngeal carcinoma. About 178 patients will be randomly assigned to receive either the doxepin spray or a placebo spray. Researchers will measure pain reduction and any drowsiness at several time points after use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
doxepin solution
What this could lead to
If effective, this spray could offer quick relief from severe swallowing pain during radiotherapy, improving quality of life for patients with nasopharyngeal carcinoma.
What could go wrong
This is a relatively small, early-stage trial. The spray may cause drowsiness or other side effects, and its pain-relieving effect may not be strong enough to be clinically useful.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 178 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2023

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Provide informed written consent. 2. Age ≥ 18 years. 3. Histologically confirmed as nasopharyngeal carcinoma, and currently undergoing radical radiotherapy or chemoradiotherapy. 4. Physical examination demonstrating the presence of radiation-induced mucositis in the oral cavity and/or oropharynx. 5. At least 4 (out of 10) patient-reported swallowing-induced pain as measured by the numeric rating scale of pain. 6. Being able to complete the questionnaires independently or with assistance. 7. ECOG Performance Status 0, 1 or 2. Exclusion Criteria: 1. Known allergy to doxepin, tricyclic antidepressants, or any known component of the drug formulation. 2. Use of a tricyclic antidepressant or monoamine oxidase inhibitor within 14 days prior to registration. 3. Current untreated or unhealed oral candidiasis or oral herpes simplex virus infection. 4. Untreated narrow angle glaucoma within 6 weeks prior to registration. 5. Untreated urinary retention within 6 weeks prior to registration. 6. Administration of cryotherapy to prevent oral mucositis within 6 weeks prior to registration. 7. Current serious heart disease or a recent history of myocardial infarction. 8. Current untreated or unresolved conditions like epilepsy, hyperthyroidism, hepatic dysfunction, delirium, and neutropenia. 9. Pregnant or lactating women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Swallowing-induced pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Southern medical university

    RECRUITING

    Guangzhou, Guangdong, 510515, China